General Information of the Compound
| Compound ID |
CP0258256
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
Show/Hide
|
||||||||||||||||||
| Synonyms |
1849590-01-7
6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione
6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
AKOS030627405
BCP18993
CS-5841
EFT 508
EFT-508
EFT508
EX-A2494
GTPL10167
HY-100022
MolPort-044-560-418
S8275
SCHEMBL17362622
Tomivosertib
Tomivosertib [INN]
Tomivosertib [USAN]
U2H19X4WBV
UNII-U2H19X4WBV
ZINC575623807
compound 23 [PMID: 29526098]
eFT-508 (eFT508)
eFT508
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C17H20N6O2
|
||||||||||||||||||
| Molecular Weight |
340.387
|
||||||||||||||||||
| Canonical SMILES |
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
Show/Hide
|
||||||||||||||||||
| InChIKey |
HKTBYUWLRDZAJK-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
1849590-01-7
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Clinical Information about the Compound
Drug 1 ( EFT508 )
| Drug Name | EFT508 | ||
|---|---|---|---|
| Company | eFFECTOR Therapeutics San Diego, CA | ||
| Indication | |||
| Target(s) | |||